Skip to main content
ASHI 51st Annual Meeting Main banner

Amir Hamidieh, MD

Professor of Pediatric Hematology/Oncology and Stem Cell Transplantation,
Tehran University of Medical Sciences
Tehran, Tehran, Iran

Dr. Hamidieh is a pioneering figure in pediatric stem cell transplantation and cell and gene therapy in the Middle East, currently serving as the Director of the Gene, Cell & Tissue Institute at Tehran University of Medical Sciences (TUMS) since 2021. He is also the Founder and Director of the Pediatric Cell & Gene Therapy Research Center (2019–present), the Innovation Center for Stem Cell and Regenerative Medicine (2018–present), and the Pediatric Stem Cell Transplantation Program at both the Children's Medical Center (2016–present) and previously at Shariati Hospital (2007–2016), all under the TUMS umbrella. As the Founder and Secretary General of the Iranian National Stem Cell Donor Network (INSCDN), and the Iranian Stem Cell Donor Program (ISCDP)—the first HLA registry in the Eastern Mediterranean—he played a foundational role in establishing unrelated HSCT in Iran. Internationally, he has served on the Board of Directors of the Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT) since 2009 and as its representative to the Worldwide Network for Blood and Marrow Transplantation (WBMT) since 2010. He has also been an executive board member of the Asia Pacific Blood and Marrow Transplantation Group (APBMT) (2013–2024) and a member of the Pediatric Diseases Working Party of the European Blood and Marrow Transplantation Group (EBMT) since 2014. Despite limited financial and human resources, he led the successful execution of over 2,100 pediatric hematopoietic stem cell transplants (HSCT) in 19 years, primarily through fundraising and the formation of highly trained teams. His efforts resulted in the creation of seven pediatric HSCT centers in Iran and the training of over 20 pediatric HSCT fellows. His work also includes extending services to patients from 13 different countries, pioneering clinical programs like photopheresis, donor lymphocyte infusion (DLI), and homemade CAR-T cell therapy, and leading national research initiatives in non-malignant hereditary disorders and gene therapy, despite severe resource limitations due to sanctions. He has authored over 210 peer-reviewed publications and more than 200 conference abstracts and continues to collaborate on international research projects, with over 50 joint publications to date.

Presentation(s):